Category Archives: Scientific publications
GM102, a low fucosylated anti-Müllerian Hormone type II Receptor (AMHRII) antibody promotes in vitro anti-tumoral activities of innate (macrophages) and adaptative (CD4+ and CD8+ T cells) immune cells
A First-In Human study of monoclonal antibody GM102 in patients with Anti-Müllerian-Hormone-Receptor II (AMHRII) positive gynecological cancers
A first-in-human study of monoclonal antibody GM102 in patients with anti- Mullerian-hormone-receptor II (AMHRII) positive gynecological cancers.
Abstract # 5542_Presented Monday, June 4, 2018
The humanized anti-human AMHRII mAb 3C23K exerts an antitumor activity against human ovarian cancer through tumor associated macrophages
Oncotarget journal published an article on GamaMabs’GM102 antibody.
Houcine Bougherara, Fariba Némati, André Nicolas, Gérald Massonnet, Martine Pugnière, Charlotte Ngô, Marie-Aude Le Frère-Belda, Alexandra Leary, Jérôme Alexandre, Didier Meseure, Jean-Marc Barret, Isabelle Navarro-Teulon, André Pèlegrin, Sergio Roman-Roman, Jean-François Prost, Emmanuel Donnadieu1, and Didier Decaudin, (2017) The humanized anti-human AMHRII mAb 3C23K exerts an antitumor activity against human ovarian cancer through tumor associated macrophages, Oncotarget
The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells, Pauline Estupina et al., Oncotarget February 2017
Oncotarget journal published an article on GamaMabs’12G4 antibody (3C23K precursor).
Pauline Estupina, Alexandre Fontayne, Jean-Marc Barret, Nathalie Kersual, Olivier Dubreuil, Marion Le Blay, Alexandre Pichard, Marta Jarlier, Martine Pugnière, Maëva Chauvin, Thierry Chardès, Jean-Pierre Pouget, Emmanuel Deshayes, Alexis Rossignol, Toufik Abache, Christophe de Romeuf, Aurélie Terrier, Lucie Verhaeghe, Christine Gaucher, Jean-François Prost, André Pèlegrin, Isabelle Navarro-Teulon, (2017) The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells, Oncotarget
The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer, Nathalie Kersual et al., mAbs October 2014
mAbs journal published an article on GamaMabs’12G4 antibody (3C23K precursor).
Nathalie Kersual, Véronique Garambois, Thierry Chardès, Jean-Pierre Pouget, Imed Salhi, Caroline Bascoul-Mollevi, Frédéric Bibeau, Muriel Busson, Henri Vié, Béatrice Clémenceau, Christian K Behrens, Pauline Estupina, André Pèlegrin & Isabelle Navarro-Teulon (2014) The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer, mAbs, 6:5, 1314-1326